

Dianon Systems, Inc. 1 Forest Parkway Shelton, CT 06484 203-926-7100 800-328-2666 dianon.labcorp.com

CLIENT INFORMATION				BILLING	INFORMATIO	ON (face she	eet & front and back of in:	surance ca	rd must be attached)
REQUESTING PHYSICIAN		NPI#		Bill: ☐ My A	Account 🗆 Insura	nce 🗆 N	ledicare \square Medicaio	I □ Pa	tient
REFERRING		NPI#		Patient Status:	☐ Hospital Inp	oatient \square	Hospital Outpatient	□ Non-H	lospital Patient
PHYSICIAN				Insurance Info	rmation: 🗆 See	attached			
				Insured Inform	ation: Name				
				Relationship t	o Patient (circle one)	Self Sp	ouse Child Other	:	
				Primary Insura	ince Co:		Aut	horization	#
				Billing Addres	S		Ins	ured #	
				Billing City, State, Zip Group #					
				Secondary Insurance Co: Authorization #			#		
				Billing Addres	S		Ins	ured #	
PATIENT INFORMATION				Billing City, St	tate, Zip		Gro	oup #	
Name (LAST, FIRST, MIDDLE)				CLINICA	L INFORMAT	ION			
Address				Collection Date:	MM / DD	/	YYYYY Time:		☐ A.M. ☐ P.M.
City, State, Zip				Number of Jars:					
Date of Birth: MM / DD /	YYYY	Sex □ M	□F				ring physician or his or in effect at Date of Ser		orized designee. hest Specificity Required
Phone Number	Race:			REQUIRED	INFORMATION	ICD-CM		ICD-CM	
MRN / PATIENT ID #	Chart #			ICD-CM		ICD-CM		ICD-CM	
Physician/Authorized Sign	nature:			IOD-OIII		IOD-OM		IOD-OW	
HISTOLOGY † Separately billa	able stains may be added	by pathologist w	hen medically nec	essary to rende	r a diagnosis.				
☐ H&E Histology (Gross & Microscopic)	†			☐ Consultation	n: On referred slides	† (send patho	ology report) 88321		
☐ (D9F-1) Direct Immunofluorescence (TgA, IgG, IgM, C3) (Michel's	Media)		☐ Consultation	n: Referred material r	equiring slide	e prep † (send pathology	report) 8	8323
☐ (D9H-1) Direct Immunofluorescence, rul		,	el's Media)		echnical Component			, ,	
	, , ,		,	o.o.o.gy	oomponent				
BIOPSY DATA (please identified)	, , , , , ,								
		Specin	nen Type		01				Signs & Symptoms
Jar # Body Site	Jar # Body Site/Descriptor (biopsy, excision)		excision)	Clinical Data					(see below for code)
1									
2									
3									
4									
5									
6									
Signs and Symptoms (DO NOT CIRC					•				
	Plaque Scar	11. Annular12. Atrophy	16. Gyrate/S 17. Hair Los		21. Pain22. Papule		•		oridement t Tissue Mass
	Scar/reexcision	13. Bullae	18. Hyperpic		23. Photodistri		3. Telangiectasia		
	Subcutaneous Mass	14. Erythema	19. Hypopig	mentation	24. Plaque	29). Vesicle		
5. Pigmented Neoplasm 10.	Tag	15. Excoriation			25. Pruritus	30). Ulcer		
MICROBIOLOGY			Additional Clinical I	History:					
008649 ☐ Aerobic Bacterial Culture, General 008482 ☐ Fungus (Mycology) Culture 008573 ☐ Viral Culture, General ☐ Other:		CPT 87070 CPT 87101							
		CPT 87252							
ID and Susceptibility at addition	nal charges per organis	m if indicated.							
When ordering tests for which Med	icare or Medicaid reimbur	sement will be so	ought, physicians sh	nould only order	tests that are med	dically nece	essary for the diagnos	sis or trea	atment of the patient
Dianon Systems Inc. is a subsidiar	y of Laboratory Corporation	on of Amorica Ho	Idinas using the br	and Labourn		,	,		- 1

1190L Rev. 02/18/2022 CT Lic # CL-0356

© 2022 Laboratory Corporation of America® Holdings. All rights reserved.

Patient, Client and Billing Information is requested for timely processing of this case. Medicare and other third party payors require that services be medically necessary for coverage, and generally do not cover routine screening tests.

= Medicare deems investigational. Medicare does not pay for services it deems investigational.

Refer to Determining Necessity of ABN Completion on Reverse

SPECIMEN LABEL INSTRUCTIONS:

- 1.) Complete the requisition with all requested information.
- 2.) Remove the required number of labels from the front of this sheet.
- 3.) Place one (1) label on each specimen container (not on the lid).

PLEASE DISPOSE OF UNUSED LABELS.

AREA:	AREA:	AREA:	AREA:
AREA:	AREA:	AREA:	AREA:
AREA:	AREA:	AREA:	AREA:
TECHNICAL COMPONENT	AREA:	ARFA:	ARFA:

Test Combination/Panel Policy

Labcorp's policy is to provide physicians, in each instance, with the flexibility to choose appropriate tests to assure that the convenience of ordering test combinations/panels does not distance physicians who wish to order a test combination/profile from making deliberate decisions regarding which tests are truly medically necessary. All the tests offered in test combinations/panels may be ordered individually using the Labcorp request form. Labcorp encourages clients to contact their local Labcorp representative or Labcorp location if the testing configurations shown here do not meet individual needs for any reason, or if some other combination of procedures is desired.

In an effort to keep our clients fully informed of the content, charges and coding of its test combinations/panels when billed to Medicare, we periodically send notices concerning customized test combinations/panels, as well as information regarding patient fees for all Labcorp services. We also welcome the opportunity to provide, on request, additional information in connection with our testing services and the manner in which they are billed to physicians, health care plans, and patients.

The CPT code(s) listed are in accordance with the current edition of *Current Procedural Terminology*, a publication of the American Medical Association. CPT codes are provided for the convenience of our clients; however, correct coding often varies from one carrier to another. Consequently, the codes presented here are intended as general guidelines and should not be used without confirming with the applicable payor that their use is appropriate in each case. All laboratory procedures will be billed to third-party carriers (including Medicare and Medicaid) at fees billed to patients and in accordance with the specific CPT coding required by the carrier. Microbiology CPT code(s) for additional procedures such as susceptibility testing, identification, serotyping, etc. will be billed in addition to the primary codes when appropriate. Labcorp will process the specimen for a Microbiology test based on source.

Determining Necessity of Advance Beneficiary Notice of Non-coverage (ABN) Completion*

- 1. Diagnose. Determine your patient's diagnosis.
- 2. **Document.** Write the diagnosis code(s) on the front of this requisition.
- 3. **Verify.** Determine if the laboratory test(s) ordered for the patient is subject to Local Coverage Determination or National Coverage Determination. This information can be located in the policies published by your Medicare Administrative Contractor (MAC), CMS, or www.Labcorp.com/MedicareMedicalNecessity.
- 4. **Review.** If the diagnosis code for your patient <u>does not</u> meet the medical necessity requirements set forth by Medicare or the test(s) is being performed more frequently than Medicare allows, an ABN should be completed.

How to Complete an Advance Beneficiary Notice of Non-coverage (ABN)

Medicare is very specific in requiring that all of the information included on the ABN be completed. Additionally, Labcorp requests that the specimen number or bar code label be included on the form. To be valid an ABN must:

- 1. Be executed on the CMS approved ABN form (CMS-R-131)
- 2. Identify the Medicare Part B Beneficiary, using the name as it appears on the patient's red, white and blue Medicare card
- 3. Indicate the test(s)/procedure(s) which may be denied within the relevant reason column
- 4. Include an estimated cost for the test(s)/procedure(s) subject to the ABN
- 5. Have 'Option 1', 'Option 2', or 'Option 3' designated by the beneficiary
- 6. Be signed and dated by the beneficiary or his/her representative prior to the service being rendered

CPT Codes:

Direct Immunofluorescence (IgA, IgG, IgM, C3)	88346, 88350x3
Direct Immunofluorescence (Fibrinogen, IgA, IgG, IgM, C3)	88346, 88350x4



Dianon Systems, Inc. is a subsidiary of Laboratory Corporation of America Holdings, using the brand Labcorp. 1190L Rev. 02/18/2022 CT Lic # CL-0356

© 2022 Laboratory Corporation of America® Holdings. All rights reserved.

 \Box

^{*}An ABN should be completed for all tests that are considered investigational (experimental or for research use) by Medicare.